Company: BIAF
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023405
Chunk: 32

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 8
Chunk 32
---
 
     58,402  
     —  
     (58,402) 
     — 
  
    Placement agent direct
    offering August 5, 2024 
     1,659  
     45.00  
     —  
     1,659 
  
    Direct offering October
    21, 2024 
     88,757  
     17.40  
     (59,544) 
     29,213 
  
    Warrant inducement February
    25, 2025 
     97,538  
     25.50  
     —  
     97,538 
  
    Public offering May 7,
    2025 
     2,408,908  
     4.50  
     (1,719,497) 
     689,411 
  
    August PIPE/Inducement
    offering August 13, 2025 
     271,490  
     10.56  
     —  
     271,490 

    Balance
    at September 30, 2025 
     3,255,840  
    $28.44  
     (1,907,548) 
     1,348,292 

Note
15. SUBSEQUENT EVENTS

In
October 2025, the Company entered into definitive agreements for the purchase and sale of 720,000 shares of common stock, par value $0.007
per share, at a purchase price of $2.50 per share in a registered direct offering priced at-the-market under Nasdaq rules. The gross
proceeds to the Company from the offering were approximately $1.8 million before deducting placement agent fees and other offering expenses
payable by the Company.

18

ITEM
2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

You
should read the following discussion and analysis of our financial condition and results of operations together with our financial statements
and the related notes appearing elsewhere in this Quarterly Report on Form 10-Q. In addition to historical information, this discussion
and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially
from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to,